AneuFix可注射生物相容性弹性体经腰穿刺栓塞治疗II型内漏的初步临床经验
这项多中心前瞻性关键性研究评估了AneuFix弹性体经腰穿刺直接注射至瘤囊治疗II型内漏合并动脉瘤增大的初步经验、技术成功率和临床获益。首批10例患者(7男3女,中位年龄78岁)的技术成功率为100%,6个月临床成功率为90%,无手术或材料相关严重不良事件及神经功能障碍。
要点
- 对II型内漏伴动脉瘤增大(>5 mm)患者,AneuFix弹性体经腰穿刺栓塞技术成功率为100%。
- 6个月临床成功率为90%,1例因内漏填充可能不充分而出现5 mm增长并内漏持续。
- 未报告手术或AneuFix材料相关的严重不良事件,未报告神经功能障碍。
核心结论
- 在少数动脉瘤增大的患者中,AneuFix可注射弹性体治疗II型内漏的初步结果显示其技术上可行、安全,且在6个月时临床有效。
研究设计与样本
- 多中心、前瞻性、关键性研究(ClinicalTrials.gov:NCT02487290),纳入II型内漏且动脉瘤增长>5 mm的患者,排除肠系膜下动脉通畅并与内漏相连者。
- 分析报告首批10例接受AneuFix治疗患者的初步经验;7男3女,中位年龄78岁(IQR 74-84),EVAR后中位动脉瘤增长19 mm(IQR 8-23 mm)。
- 在锥形束CT及软件引导下经腰穿刺内漏腔,行内漏腔造影显示所有与内漏相连的腰动脉,将AneuFix弹性体注入内漏腔及腰动脉短段。
- 主要终点为技术成功,定义为24小时内CTA评估内漏腔成功填充;次要终点包括6个月CTA无AAA增长(临床成功)、严重不良事件、再干预和神经功能异常。
- CTA随访于1天及3、6、12个月进行。
主要发现
- 技术成功率为100%,所有治疗患者均成功穿刺内漏腔并注射AneuFix。
- 6个月临床成功率为90%。
- 1例患者出现5 mm增长并内漏持续,可能因内漏填充不充分。
- 未报告手术或AneuFix材料相关的严重不良事件;未报告神经功能障碍。
关键数值与推荐
- 技术成功定义为24小时内CTA评估内漏腔成功填充,本研究中为100%。
- 临床成功定义为6个月CTA无AAA增长,本研究中为90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文在结论中自述为小样本患者的初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to assess the initial experience, technical success, and clinical benefit of AneuFix (TripleMed, Geleen, the Netherlands), a novel biocompatible and non-inflammatory elastomer that is directly injected into the aneurysm sac by a translumbar puncture in patients with a type II endoleak and a growing aneurysm. MATERIALS AND METHODS: A multicenter, prospective, pivotal study was conducted (ClinicalTrials.gov:NCT02487290). Patients with a type II endoleak and aneurysm growth (>5 mm) were included. Patients with a patent inferior mesenteric artery connected to the endoleak were excluded for initial safety reasons. The endoleak cavity was translumbar punctured with cone-beam computed tomography (CT) and software guidance. Angiography of the endoleak was performed, all lumbar arteries connected to the endoleak were visualized, and AneuFix elastomer was injected into the endoleak cavity and short segment of the lumbar arteries. The primary endpoint was technical success, defined as successful filling of the endoleak cavity with computed tomography angiography (CTA) assessment within 24 hours. Secondary endpoints were clinical success defined as the absence of abdominal aortic aneurysm (AAA) growth at 6 months on CTA, serious adverse events, re-interventions, and neurological abnormalities. Computed tomography angiography follow-up was performed at 1 day and at 3, 6, and 12 months. This analysis reports the initial experience of the first 10 patients treated with AneuFix. RESULTS: Seven men and 3 women with a median age of 78 years (interquartile range (IQR), 74-84) were treated. Median aneurysm growth after endovascular aneurysm repair (EVAR) was 19 mm (IQR, 8-23 mm). Technical success was 100%; it was possible to puncture the endoleak cavity of all treated patients and to inject AneuFix. Clinical success at 6 months was 90%. One patient showed 5 mm growth with persisting endoleak, probably due to insufficient endoleak filling. No serious adverse events related to the procedure or AneuFix material were reported. No neurological disorders were reported. CONCLUSION: The first results of type II endoleak treatment with AneuFix injectable elastomer in a small number of patients with a growing aneurysm show that it is technically feasible, safe, and clinically effective at 6 months. CLINICAL IMPACT: Effective and durable embolization of type II endoleaks causing abdominal aortic aneurysms (AAA) growth after EVAR is challenging. A novel injectable elastic polymer (elastomer) was developed, specifically designed to treat type II endoleaks (AneuFix, TripleMed, Geleen, the Netherlands). Embolization of the type II endoleak was performed by translumbar puncture. The viscosity changes from paste-like during injection, into an elastic implant after curing. The initial experience of this multicentre prospective pivotal trial demonstrated that the procedure is feasible and safe with a technical success of 100%. Absence of AAA growth was observed in 9 out of 10 treated patients at 6 months.
引用
- Smorenburg SPM, Lely RJ, Kelckhoven BV, et al. Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks. J Endovasc Ther. 2023. PMID: 37073926. doi:10.1177/15266028231165731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。